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Summary
Passive properties of the myocardium influence diastolic filling and cardiac output. In heart 
failure, changes in contributors to the passive properties of the ventricle, such as titin and 
collagen, and loss of the metabolic enzyme creatine kinase, increase resistance to filling 
resulting in diastolic dysfunction. Pulmonary artery hypertension (PAH) arises from inter‐
actions between the pulmonary vasculature and the right ventricle (RV) which ultimately 
leads to RV failure. Beta1- adrenergic receptor blockers (BB) act on the myocardium and 
are beneficial in left heart failure but are not used in PAH. We investigated whether BB 
improved survival and RV function in a rat model of PAH. Rats were injected with mono‐
crotaline (60 mg/kg) to induce PAH and RV failure, or saline as controls (CON). When PAH 
was established, rats were treated with metoprolol (10 mg/kg per day) (MCT+BB) or vehi‐
cle (sucrose) (MCT); CON were treated with vehicle. In vivo measurement of RV compli‐
ance using pressure–volume catheter, indicated diastolic dysfunction in the RV of MCT 
rats was improved with BB treatment. Expression of creatine kinase protein and mRNA 
was lower in MCT rats compared to CON, with a trend for reversion by BB treatment. 
Isolated CON RV myocytes had a positive contraction response to faster pacing, whereas 
it was negative in MCT. MCT+BB cells had an intermediate response, indicating improved 
ability to respond to increased demand. BB improved diastolic function, partially restored 
metabolic enzymes and augmented contractility in PAH. These data support the hypoth‐
esis that BB may be beneficial in PAH by supporting RV function.
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1  | DIASTOLIC DYSFUNCTION AND 
HEART FAILURE
Ventricular stroke volume is influenced by end- diastolic volume 
through the Frank- Starling mechanism. This dictates that as the 
ventricle fills, sarcomeres are stretched along the ascending limb 
of the length- tension relationship, resulting in greater myofilament 
force generation and ejection of blood. In pathological conditions, 
such as heart failure, increased resistance to ventricular filling may 
reduce end- diastolic volumes and thereby cause a decrease in 
stroke volume and cardiac output. This limits the ability of the heart 
to respond to an increase in demand, which is a definition of heart 
failure. Myocardial passive properties are implicated in diastolic 
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dysfunction. During normal filling, a major contribution to passive 
tension is thought to come from titin, an elastic protein that spans 
half of the sarcomere from Z- disk to M- line. Changes in the prop‐
erties of titin in disease are known to include a shift in isoform dis‐
tribution from the more compliant N2BA isoform to the shorter and 
stiffer N2B isoform, oxidation of cysteine residues, and phosphor‐
ylation status.1 The extracellular matrix also contributes to passive 
tension in volume- overload situations. Proliferation of collagen fi‐
bres (fibrosis) and greater cross- linking between fibres can increase 
myocardial stiffness2 and mechanisms involving the myofilaments 
and cytoskeleton may also be relevant.
In addition, metabolic state also influences cardiac passive proper‐
ties. Creatine kinase (CK) catalyses the reversible transfer of inorganic 
phosphate from creatine phosphate to ADP, generating ATP. 
In cardiac muscle there are four isoforms: CK-m (muscle) that 
accounts for about 70% of total CK, of which 10%- 30% is bound 
to the myofilament protein myomesin; CK- mt (mitochondrial) 20%- 
30% total; CK-b (brain) and CK-mb (muscle/brain) are both found 
in low abundance but have been reported to increase in disease. 
CK is located in areas with high ATP turnover such as mitochondria, 
myofilaments, sarcoplasmic reticulum and sarcolemma.3 This func‐
tional coupling with ATPases helps maintain a high local ATP:ADP 
essential for, e.g. cross- bridge cycling and Ca2+ uptake.4,5 Indeed, a 
consequence of ADP accumulation is an increase in passive tension 
in the heart due to rigor- like cross- bridge formation.6,7 CK expres‐
sion decreases in left heart failure,8 which may have multiple reper‐
cussions in the cardiac myocyte.
2  | PULMONARY ARTERY HYPERTENSION 
AND DIASTOLIC DYSFUNCTION
Pulmonary artery hypertension (PAH) is a complex disease with 
 interactions between the pulmonary vasculature (PV) and the right 
ventricle (RV). It is caused by increased constriction of the PV which 
increases vascular resistance and hence RV afterload. This eventu‐
ally leads to RV failure, which is the most common cause of death 
in PAH.
In the study of Rain et al9 human PAH patients were found to 
have diastolic dysfunction. There was increased stiffness of myo‐
cardium, increased collagen content and reduced phosphorylation 
of titin with no shift in titin isoforms. RV failure has also been stud‐
ied in animal models of PAH.10 In the monocrotaline rat model of 
PAH, RV heart failure occurs 3- 4 weeks after a single injection of 
monocrotaline. The onset of heart failure in this model was associ‐
ated with diastolic dysfunction.11 When a reduced dose of mono‐
crotaline was used to induce stable hypertrophy, diastolic function 
was preserved.12
We have used the monocrotaline rat model to study RV failure 
in PAH. The end diastolic pressure–volume relationship (EDPVR) was 
measured using a Millar catheter inserted into the RV of anesthe‐
tized animals. The EDPVR was significantly steeper in monocrotaline- 
injected rats (MCT; [FAIL in Fowler et al.13]) compared to saline- injected 
controls (CON), indicating reduced compliance and greater resistance 
to ventricular filling and confirming the presence of diastolic dysfunc‐
tion. This was not linked to increased fibrosis, therefore changes in the 
properties of single ventricular myocytes were investigated.
Intact single myocytes were attached to glass fibres and electri‐
cally stimulated to contract while being stretched. The end - diastolic 
force- length relationship (EDFLR) was recorded and the slope was 
found to be significantly steeper in RV myocytes from MCT rats, in 
accord with the steeper EDPVR in vivo. Furthermore, it was observed 
that RV myocytes (but not left ventricular myocytes) from MCT rats 
had significantly shorter diastolic sarcomere lengths compared to 
CON animals, in the absence of changes in either diastolic intracel‐
lular Ca2+ (measured with Fura- 2) or myofilament Ca2+ sensitivity. 
Application of an intracellular Ca2+- buffer (BAPTA- AM) increased sar‐
comere length; subsequent addition of a myofilament cross- bridge in‐
hibitor (40 mmol L−1 BDM) caused further lengthening. The sarcomere 
lengthening effect of BDM was significantly greater in MCT than CON, 
suggesting a cross- bridge based, Ca2+- independent mechanism.
Western blot analysis showed a significant reduction in protein 
levels of CK in the RV of MCT rats. Furthermore, when the sarcolemma 
was permeabilised with saponin and cells incubated with exogenous 
CK and creatine phosphate, the sarcomere length of RV myocytes 
from MCT rats significantly increased. Conversely in CON myocytes, 
inhibition of CK shortened sarcomere length. This indicated that 
loss of CK in MCT myocytes impaired RV diastolic function. In intact 
CON RV myocytes, the relationship between stimulation frequency 
and myocyte shortening was relatively flat over the range 1- 7 Hz, in 
contrast the relationship in MCT myocytes was steeply negative. A 
similar steep negative relationship occurred in CON myocytes follow‐
ing CK inhibition. We interpreted this as a decreased ability of MCT 
myocytes to respond to an increase in demand, which is a definition 
of heart failure. We concluded that decreased CK expression leads 
to diastolic dysfunction, via local reduction in ATP:ADP ratio and 
thus to Ca2+- independent force production and diastolic sarcomere 
shortening.13
3  | BETA- BLOCKER TREATMENT OF PAH
There is currently no cure for PAH and novel treatments are needed 
to resolve this. The importance of RV function in PAH patient sur‐
vival indicates the heart is a potential therapeutic target. However, 
available therapies primarily cause vasodilation of the PV and current 
guidelines do not include treatments specifically for the RV.14 It was 
proposed that established treatments for left ventricular failure may 
be beneficial to the failing RV in PAH.15,16 Beta- adrenoceptor block‐
ers (beta- blockers) are a primary treatment for left ventricular failure 
which slow the cardiac remodelling caused by chronic sympathetic 
activation. Small clinical trials have tested their use in PAH without 
finding adverse effects.17
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Pre- clinical studies have shown beta- blockers improved animal sur‐
vival, vascular remodelling and cardiac function in PAH. However, the 
mechanisms contributing to improved cardiac function have not been 
investigated. We therefore proposed the first study to investigate the 
mechanisms by which beta- blockade may benefit RV myocytes in PAH. 
From our previous findings, discussed in the preceding section, we hy‐
pothesized that beta- blockade would improve diastolic dysfunction and 
the response to increased demand in monocrotaline- treated rats, and 
that these changes would be associated with  increased levels of CK.
Experiments were conducted with local ethical approval and 
in accordance with UK Home Office and European Parliament 
Directive 2010/63/EU guidelines on the use of animals in research. 
Methodological details can be found in Fowler et al13 PAH and RV fail‐
ure were induced in rats by a single IP injection (60 mg/kg) of mono‐
crotaline. When PAH was established, metoprolol in sucrose solution 
(10 mg/kg per day, MCT+BB) or sucrose solution (MCT) was admin‐
istered by voluntary syringe feeding. Control animals (CON) were 
 injected with saline and given sucrose.
As we were specifically interested in the cardiac effects of 
beta- blocker treatment we chose to use metoprolol: it is beta- 1 
specific (the predominant beta- adrenoceptor in heart), in com‐
mon clinical use, and lacks the vasodilatory effects of carvedilol18 
and nebivolol.19 The human equivalent dose of 10 mg/kg per day 
was 1.62 mg/kg per day, within the typical clinical dose range for 
a 75 kg patient (0.17- 2.67 mg/kg per day). Animals were killed 
when showing external signs of heart failure (weight loss, lethargy, 
laboured breathing, piloerection) (see Fowler et al13). Data from the 
three experimental groups were compared by one- way ANOVA. 
Holm- Sidak (n numbers equal) or Tukey (n numbers uneven) post 
hoc tests were used following parametric ANOVA, or Dunn post 
hoc tests following non- parametric ANOVA, as recommended by 
the statistical package (GraphPad Prism 7). Statistical differences 
are reported as P < .05.
Treatment with metoprolol delayed the median time to the onset 
of heart failure signs from 23 days post MCT (n = 12) to 31 days 
(n = 15) (P < .01 Mantel- Cox test). To assess the mechanisms of BB 
action, MCT animals were compared to CON and MCT+BB animals 
at 23 ± 1 days after a single injection of saline or MCT. Ventricular 
weights are given in Table 1 and show RV hypertrophy in both PAH 
groups. EDPVRs were measured in anaethetised rats by Millar cath‐
eter in the RV during vena cava occlusion (Figure 1A, see Fowler 
et al.13 for details of methodology). The EDPVR from MCT animals 
was significantly steeper than CON, indicating diastolic dysfunc‐
tion. The mean value for MCT+BB was intermediate (Figure 1B) 
representing an improvement in diastolic function. Consistent 
with observations in whole animals, the resting sarcomere length 
of RV myocytes showed a progressive increase CON > MCT+BB > 
MCT (Figure 1C). BB treatment did not affect diastolic or systolic 
 pulmonary pressure, consistent with previous reports using other 
BB18,19, but did  improve the ratio of end systolic pressure–volume 
relationship (ESPVR) to arterial elastance (Ea), an indicator of in vivo 
contractility/afterload (see Table 1).
T A B L E  1   Animal and organ characteristics of rats on the median day of heart failure signs (CON and MCT+BB) or day of heart failure signs 
(MCT)
CON MCT MCT±BB
Rats/group 15 13 14
Organ weights
Body weight (g) 301 ± 6 257 ± 4* 274 ± 8*
Heart/body weight (mg/g) 3.65 ± 0.16 4.82 ± 0.23* 5.18 ± 0.30*
Lung/body weight (mg/g) 4.76 ± 0.39 8.74 ± 0.46* 9.72 ± 0.37*
RV/body weight (mg/g) 0.64 ± 0.06 1.20 ± 0.06* 1.14 ± 0.06*
LV+S/body weight (mg/g) 2.20 ± 0.10 2.55 ± 0.13 2.58 ± 0.09*
RV:LV+S ratio 0.30 ± 0.04 0.48 ± 0.03* 0.45 ± 0.02*
Rats/group 9 7 5
In vivo
End systolic pressure (mm Hg) 39.5 ± 2.7 83.2 ± 5.2* 101.8 ± 9.9*
End diastolic pressure (mm Hg) 4.6 ± 0.7 9.6 ± 0.7* 9.9 ± 2.3*
Stroke volume (μL) 110 ± 10 48 ± 10* 65 ± 5*
ESPVR/Ea 0.93 ± 0.27 0.27 ± 0.06* 0.57 ± 0.20
EDPVR (mm Hg/μL) 0.05 ± 0.01 0.19 ± 0.06* 0.09 ± 0.02
On the final experimental day there was RV hypertrophy in MCT and MCT+BB animals compared with CON. RV systolic and diastolic pressure were in‐
creased in MCT and MCT+BB animals. Ventriculo- arterial coupling was impaired in MCT (reduced end- systolic pressure–volume relationship (ESPVR) to 
arterial elastance (Ea) ratio) but not different in MCT+BB compared to CON.
*P < .05, one- way ANOVA. Intergroup differences between variables were identified using Dunn’s (RV:LV+S and End systolic pressure) or Tukey’s (all 
others) post hoc test. CON, control; MCT, monocrotaline treated; MCT+BB, monocrotaline + beta-blocker treated; LV, left ventricle; RV, right ventricle; S, 
septum
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F I G U R E  2   Loss of creatine kinase was attenuated by BB treatment. (A), Creatine kinase (CK) isoenzyme distribution in cardiac muscle consists 
of 70% muscle (CK- m), 20% mitochondrial (CK- mt) and the remainder brain (CK- b) isoforms. Expression of mRNA for the predominant CK isoforms 
were reduced in MCT+BB and MCT rats compared to CON. Mean values for MCT+BB were greater than MCT but not statistically so. N = 10 rats 
per group. One- way ANOVA with Holm- Sidak post hoc test. (B), Western blots for CK- m and CK- mt. C, CON; B, MCT+BB; M, MCT. Common CON 
samples were run on each gel as calibrator samples where N precluded use of a single gel. Blots were stripped and re- probed for GAPDH hence 
changes in background density. Protein levels for (C), CK- m (N = 6- 10 rats per group) were decreased in MCT compared to CON, levels for MCT+BB 
were intermediate. One- way ANOVA with Dunn’s post hoc test. (D) A similar trend was observed in CK- mt expression, although differences were not 
statistically significant (N = 6- 7 rats per group). Protein levels were normalised to GAPDH and expressed relative to the mean value in CON. *P < 0.05 
CON, control; MCT, monocrotaline treated; MCT+BB, monocrotaline + beta-blocker treated
F I G U R E  1   Beta- Blocker treatment improves EDPVR and increases resting sarcomere length. (A), PV relationships from a CON (black), 
MCT+BB (blue) and MCT (red) animal. The EDPVR was recorded during progressive vena cava occlusion. The loops from the three groups are 
displaced along the x- axis and averaged for clarity. (B), There was a significantly steeper EDPVR in MCT (N = 7 animals) than CON (N = 10 
animals) (P < .05) indicating diastolic dysfunction in MCT. The relationship for MCT+BB (N = 5 animals) was intermediate indicating an 
improvement in diastolic function. One- way ANOVA with Tukey post hoc test. (C), In isolated RV myocytes resting sarcomere length progressively 
shortened CON > MCT+BB > MCT (n = 30 cells from N = 6 rats per group). * P < .05, one- way ANOVA with Holm- Sidak post hoc test. CON, 
control; MCT, monocrotaline treated; MCT+BB, monocrotaline + beta-blocker treated; EDPVR, end-diastolic pressure-volume relationship
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Our previous observations had linked CK to these changes, 
Figure 2 shows the levels of mRNA for CK- m and CK- mt (Figure 2A) 
were significantly reduced in MCT vs CON. Protein levels for CK- m 
(Figure 2B, C) were also significantly lower in MCT. Consistent with 
our previous report, CK- mt tended to be reduced in MCT by around 
20% (Figure 2D). There were no significant differences in the levels 
of CK- m and CK- mito, mRNA or protein levels between MCT+BB 
and MCT. However, in each of the four comparisons, mean values 
for MCT+BB were intermediate between CON and MCT indicating 
a trend for improvement. Furthermore, we have presented data for 
CK mRNA and protein expression, but this is not always synonymous 
with enzyme activity, particularly if the in situ environment in failing 
hearts has increased oxidative stress20 or reduced substrate availabil‐
ity, both of which are thought to decrease CK activity. It is interesting 
to note that the use of beta- blockers to improve CK function is con‐
sistent with previous findings in a model of myocardial infarction.21
At low stimulation frequency (1 Hz) MCT myocytes had greater 
sarcomere shortening (Figure 3A) than CON and MCT+BB, which 
we believe is related to the longer action potential duration in MCT 
myocytes promoting greater loading of Ca2+ stores.22 However, when 
demand was increased by increasing stimulation frequency, CON my‐
ocytes showed a positive or flat contraction–frequency relationship 
compared with a negative relationship in MCT. Myocytes from beta- 
blocker treated rats had an intermediate relationship, such that frac‐
tional shortening was not different to CON at any frequency and was 
significantly greater than MCT at 7 Hz.
4  | CONCLUSIONS
Data for CON and MCT groups confirm the findings from our previous 
study.13 In addition, we show that parameters modulated by PAH consist‐
ently show means intermediate to CON and MCT following beta- blocker 
therapy. This suggests beta- blocker treatment may contribute to delaying 
the onset of heart failure by reducing maladaptive cellular remodelling 
within the RV. That these effects on the myocardium were achieved in 
the absence of improvement in lung weights or pulmonary artery pres‐
sure suggest they are due to direct effects on the myocardium. This inter‐
pretation would support the use of beta- blockers as an adjunct to, rather 
than a replacement for, conventional treatments for PAH. Despite in‐
creasing pre- clinical evidence supporting a beneficial effect and revealing 
their mode of action, the use of beta- blockers to treat PAH is at present 
controversial,17 and further data from clinical trials are required.
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